Alpha-synuclein

Alpha-synuclein

Blood test may confirm parkinsons diagnosis

Alpha-synuclein Antibody moves a step closer

Monday, 14 November 2016

Therapeutic projects against top target protein alpha-synuclein continue to march through clinical testing and closer to patient hands. Yesterday biotechnology company Prothena announced results from its Phase Ib trial of PRX002, an antibody under investigation as a treatment to slow…

Vaccine for Parkinson’s Reports Positive Results from Boost Study

Monday, 12 September 2016

New study results from Austrian biotech AFFiRiS support continued development of its vaccine against the key Parkinson’s protein alpha-synuclein. Today the company announced its “boost” follow-up study — funded with a $1.04 million grant from The Michael J. Fox Foundation…

Another Piece of the Alpha-synuclein Puzzle Revealed

Monday, 25 July 2016

Research on alpha-synuclein, a lead target for therapy to slow or stop Parkinson’s and potential marker of disease progression, is quickly advancing, and scientists are learning more about this protein’s role in Parkinson’s disease (PD). Recently, researchers discovered how this…

More Alpha-Synuclein in Spinal Fluid Linked to Faster Cognitive Decline

Measuring Parkinson’s Protein throughout Body

Saturday, 19 March 2016

Alpha-synuclein — the protein that clumps in brain cells of people with Parkinson’s — is not only a therapeutic target but also may be a measure of disease. Today, The Michael J. Fox Foundation (MJFF) launched the Systemic Synuclein Sampling Study…

Who’s to Blame? Finding Toxic Alpha-synuclein

Monday, 28 April 2014

Alpha-synuclein shoulders a lot of blame in Parkinson’s disease (PD). This protein clumps in the cells of all Parkinson’s patients, leading to cell dysfunction and cell death. But not all alpha-synuclein may be bad. Scientists do not yet know the…

News in Context: Parkinson’s Biomarker May Be Only Skin Deep

News in Context: Parkinson’s Biomarker May Be Only Skin Deep

Monday, 13 January 2014

Recently researchers from Beth Israel Deaconess Medical Center in Boston published a paper in Neurology on their findings that alpha-synuclein levels in nerve cells found in the skin differed between Parkinson’s patients and healthy controls. We talked to Roy Freeman,…

More Alpha-Synuclein in Spinal Fluid Linked to Faster Cognitive Decline

Finding the Origin of a Toxic Species

Wednesday, 11 September 2013

Since it’s discovery in 1997, it has become increasingly clear that the protein alpha-synuclein is closely associated with Parkinson’s disease (PD). But while it’s known that all people with PD experience a build-up of alpha-synuclein in their brains (called Lewy Bodies), it’s…

Australian Parkinson’s disease research shows promise

Monday, 24 June 2013

A REVOLUTIONARY new drug to fight Parkinson’s disease has shown promise in halting its progression. Victorian researchers have spent six years developing a new synthetic compound which they hope will form the next generation of therapies for the debilitating neurological…

More Alpha-Synuclein in Spinal Fluid Linked to Faster Cognitive Decline

Study: Alpha-synuclein ‘Acts Like a Virus’

Saturday, 4 May 2013

Clumps of the protein alpha-synuclein are common to the brains of all people with Parkinson’s; unfortunately, there are more questions than answers as to whether and how alpha-synuclein plays a direct causative role in the disease. For this reason, scientists are investigating…

More Alpha-Synuclein in Spinal Fluid Linked to Faster Cognitive Decline

Alpha-Synuclein Imaging Consortium Publishes First Paper

Tuesday, 19 February 2013

Clumps of the protein alpha-synuclein accumulate in the brains of all people with Parkinson’s disease (PD). Finding ways to break up, clear, or eliminate the toxicity of these clumps could go a long way toward finding a disease-modifying treatment for…